Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient

Annals of Pharmacotherapy

Volumn 44, Issue 4, 2010, Pages 764-767

  Roustit, Matthieu ^a   Blondel, Emeline ^b   Villier, Céline ^a   Fonrose, Xavier ^a   Mallaret, Michel P ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b Aix les Bains Hospital   (France)

Author keywords

Cotrimoxazole; CYP2C8; Drug drug interaction; Hypoglycemia; Repaglinide; Sulfamethoxazole; Trimethoprim; Trimethoprim sulfamethoxazole

Indexed keywords

AMIODARONE; COTRIMOXAZOLE; CREATININE; ESOMEPRAZOLE; FUROSEMIDE; GLUCOSE; PERINDOPRIL; REPAGLINIDE;

AGED; ARTICLE; CASE REPORT; CLINICAL ASSESSMENT; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPOGLYCEMIA; MICROANGIOPATHY; OSTEOARTHRITIS; PATIENT EDUCATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TOTAL HIP PROSTHESIS; URINARY TRACT INFECTION;

AGED; ANTI-INFECTIVE AGENTS, URINARY; BLOOD GLUCOSE; CARBAMATES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC NEUROPATHIES; DRUG INTERACTIONS; ENERGY INTAKE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; PIPERIDINES; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; URINARY TRACT INFECTIONS;

EID: 77950610411     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M597     Document Type: Article

References (18)

1. Wen X, Wang JS, Backman JT, Laitila J, Neuvonen PJ. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos 2002;30:631-635 (Pubitemid 34579094)
2. Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 2003;56:305-314 (Pubitemid 37059658)
3. Niemi M, Kajosaari LI, Neuvonen M, Backman JT, Neuvonen PJ. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br J Clin Pharmacol 2004;57:441-447 DOI 10.1046/j.1365-2125. 2003.02027.x (Pubitemid 38519649)
4. Product information. Prandin (repaglinide). Bagsvajrd, Denmark: Novo Nordisk A/S, June 2006.
5. Horn JR, Hansten PD, Chan L-N. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-680 DOI 10.1345/aph.1H423 (Pubitemid 46625492)
6. The Uppsala Monitoring Centre. The use of the WHO -UMC system for standardised case causality assessment. www.who-umc.org (accessed 2009 Nov 3).
7. Marbury TC, Ruckle JL, Hatorp V, et al. Pharmacokinetics of repaglin- ide in subjects with renal impairment. Clin Pharmacol Ther 2000;67:7-15. DOI 10.1067/mcp.2000.103973 (Pubitemid 30078382)
8. Schumacher S, Abbasi I, Weise D, et al. Single- and multiple-dose phar- macokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 2001;57:147-152 (Pubitemid 32449136)
9. Rosini JM, Martinez E, Jain R. Severe hypoglycemia associated with use of trimethoprim/sulfamethoxazole in a patient with chronic renal insufficiency (letter). Ann Pharmacother 2008;42:593-594 DOI 10.1345/aph.1K558 (Pubitemid 351521977)
10. Strevel EL, Kuper A, Gold WL. Severe and protracted hypoglycaemia associated with co-trimoxazole use. Lancet Infect Dis 2006;6:178-182 DOI 10.1016/S1473-3099(06)70414-5 (Pubitemid 43267643)
11. Khamaisi M, Leitersdorf E. Severe hypoglycemia from clarithromycin- repaglinide drug interaction. Pharmacotherapy 2008;28:682-684 DOI 10.1592/phco.28.5.682 (Pubitemid 351620035)
12. Tornio A, Niemi M, Neuvonen M, et al. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. Clin Pharmacol Ther 2008;84:403-411 DOI 10.1038/clpt.2008.34
13. Rolan PE. Plasma protein binding displacement interactions - why are they still regarded as clinically important? Br J Clin Pharmacol 1994;37:125-128
14. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002;71:115-121 DOI 10.1067/mcp.2002. 121829 (Pubitemid 34271114)
15. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglin- ide. Clin Pharmacokinet 2002;41:471-483 (Pubitemid 34804160)
16. Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 2005;44:1209-1225 (Pubitemid 41832564)
17. Niemi M, Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide phar-macokinetics. Clin Pharmacol Ther 2005;77:468-478 DOI 10.1016/j.clpt.2005. 01.018 (Pubitemid 40824960)
18. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacody- namics of repaglinide and nateglinide. J Clin Pharmacol 2008;48:311-321 DOI 10.1177/0091270007311569 (Pubitemid 351257770)